REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: drug combo plus stem cell transplant shows promise
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can help people with large B-cell lymphoma that has come back or not responded to treatment. About 25 adults will receive the combination, followed by more epcoritamab after t…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 01, 2026 22:00 UTC
-
New drug cocktail ViPOR targets tough lymphomas in phase II trial
Disease control Recruiting nowThis phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to boost CAR-T success in hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug odronextamab before and after standard CAR-T cell therapy can help people with diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 34 adults who have already tried at least two other therapies will r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug duo aims to outsmart tough lymphoma
Disease control Recruiting nowThis trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo approach aims to boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving the drug epcoritamab before and after CAR-T cell therapy can help people with relapsed or refractory large B-cell lymphoma. About 31 adults will receive epcoritamab injections, then CAR-T cells, and possibly more epcoritamab if lymphoma remains. Th…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo aims to tackle tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining two targeted drugs, loncastuximab tesirine and mosunetuzumab, can shrink tumors in people with diffuse large B-cell lymphoma that has relapsed or become resistant. The study will enroll 36 adults and measure how many patients respond and…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug may help more patients get Life-Saving CAR-T therapy
Disease control Recruiting nowThis study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New trial aims to bring targeted lymphoma drugs to minority patients
Disease control Recruiting nowThis phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Engineered immune cells take on HIV-Linked cancers in first human trial
Disease control Recruiting nowThis study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Vitamin c boost: could high doses help chemo fight tough blood cancers?
Disease control Recruiting nowThis study tests whether adding high-dose vitamin C (ascorbic acid) to standard chemotherapy can help kill cancer cells better in people with certain blood cancers that have returned or not responded to treatment. It includes adults with relapsed or refractory lymphoma, clonal cy…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Poop pills could help CAR t therapy work better for lymphoma patients
Disease control Recruiting nowThis study tests whether giving fecal transplants from healthy donors can repair gut damage caused by antibiotics and chemotherapy in lymphoma patients receiving CAR T-cell therapy. About 56 adults with relapsed or hard-to-treat lymphoma will be randomly assigned to get either th…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can booster drugs keep lymphoma in check after CAR t therapy?
Disease control Recruiting nowThis study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Radiation before CAR T-Cell therapy: a new hope for tough lymphoma?
Disease control Recruiting nowThis early-phase trial tests whether giving radiation to all active cancer spots before CAR T-cell infusion can help control large B-cell lymphoma that has come back or not responded to treatment. Nine adults with relapsed or refractory lymphoma will receive targeted radiation du…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC